Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Find out more about travel and accommodation at ESMO Asia Congress 2024
AI model TORCH achieved robust performance
The ESMO Immuno-Oncology Congress 2024 will take place at the Palexpo exhibition centre in Geneva, Switzerland
Evidence for efficacy is based on the results from the QUILT-3.032 study
Find here instructions to assist with your presentation
Industry partners: find out how to get involved
ESMO’s membership in the CMA presents an opportunity to secure the inclusion of critical cancer drugs on the ‘Union list of critical medicines’ and prevent their shortages across Europe
Find out the ESMO Immuno-Oncology Congress 2024 Scientific Co-Chairs and Scientific Committee Experts
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.